TRAVERE THERAPEUTICS, INC. Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic
TRAVERE THERAPEUTICS, INC. (TVTX) reported Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic of -$59.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic · last filed 2025-10-30
- TRAVERE THERAPEUTICS, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2024-09-30 was -$59.00K.
| Period end | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 3 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 9 month |
|---|---|---|
| 2024-09-30 | -$59.00K 10-Q · filed 2025-10-30 | -$919.00K 10-Q · filed 2025-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |